PARIS (dpa-AFX) – Sanofi (SNY, SAN.PA) said phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo. In both studies, lu…
Sanofi: Lunsekimig Meets Primary, Key Secondary Endpoints In Phase 2 Respiratory Studies
Source: Finanznachrichten.de
Read Full Story →
